NCCN Guidelines Version 1.2022
- Acute Lymphoblastic Leukemia
NCCN Guidelines with Evidence Blocks Version 1.2022
Basic Resources (English) Version 2.2020
Core Resources (English) Version 2.2020
Enhanced Resources (English) Version 2.2020
Acute Lymphoblastic Leukemia (adult)-English Version 2021
Acute Lymphoblastic Leukemia (adult)-Russian Version 2021
Calendar of Events
Continuing Education
Toxicities of CAR T-Cell Therapy: Beyond CRS and Neurotoxicity
Recorded Presentation from the NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia
New Treatment Options and Toxicity Management in Acute Lymphoblastic Leukemia
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Translations
Chinese Version 1.2022
French Version 1.2022
Italian Version 4.2021
Japanese Version 1.2022
Spanish Version 1.2022
Harmonized
English (Africa) Version 1.2022
Disclosure Policy
Panel Member Disclosures
Panel Member Disclosures by Meeting Date
End User License Agreement